REG - Eden Research plc - New Major Crop Use for Mevalone in France

Eden ResearchAnnouncement

02/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211202:nRSB2982Ua&default-theme=true

RNS Number : 2982U  Eden Research plc  02 December 2021

2(nd) December 2021

 

Eden Research plc

("Eden" or "the Company")

 

New Major Crop Use for Mevalone® in France

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable
biopesticides and plastic-free formulation technology for use in global crop
protection, animal health and consumer products industries, is pleased to
announce that the French regulatory authority ANSES has granted full
authorisation of Eden's biofungicide Mevalone® for use on pome fruits (such
as apples and pears) to prevent post-harvest storage diseases.

 

France produces close to 1.6 million tonnes of apples annually and exports
almost half of that volume. France is consistently among the top three apple
producing countries in the EU.

 

This authorisation represents the first full authorisation for a major new use
and the first use of Mevalone on pome fruit after an emergency authorisation
was granted in 2019. The original emergency authorisation was granted as apple
growers are coming under increasing pressure to protect their harvests while
the list of available conventional treatments are being reduced due to
regulatory action.

 

Many conventional fungicide products have relatively long pre-harvest
intervals (the minimum time allowed between application of a pesticide and
harvest) because they leave detectable chemical residues. This means that they
cannot be applied to a crop in the critical last weeks of the season when
fruit can be vulnerable to damage to the skin leading to rot during storage
and ultimately, food loss.  Collectively, post-harvest diseases cause
significant economic losses worldwide on an annual basis, with fruit losses
ranging from 5 to 20%.

 

Fortunately, Mevalone® offers growers a sustainable alternative, as it is
based on natural plant active ingredients which are exempt from EU crop
residue limits and can be applied up to three days before harvest,
significantly reducing the risk of loss to farmers and the generation of food
waste.

 

This latest authorisation is a significant addition to the existing Mevalone®
label in France, where it is already approved for use on grapes to control
botrytis and distributed by Sumi Agro France.

 

Sean Smith, Chief Executive Officer of Eden Research plc, said:

 

"The new use of Mevalone on apples, which are classed as a major crop in
France, is an exciting development for Eden, and grows our addressable market
in this key European territory. Mevalone has significant potential in several
market segments, and we are focussed on developing the product to meet the
needs of farmers who are increasingly unable to use many conventional
chemicals due to more stringent regulations.  We look forward to receiving
further product authorisations in due course and further helping farmers
efficiently and sustainably provide food for our growing population."

 

For further information contact:

 

 Eden Research plc                                                     www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                            01285 359 555

Alex Abrey

 Cenkos Securities plc (Nominated advisor and broker)
 Giles Balleny / Camilla Hume / Mark Connelly (corporate finance)      020 7397 8900

Michael Johnson (sales)

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                    eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

Johanna Pemberton

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has two products currently on the market:

 

Mevalone® is a foliar biofungicide which initially targets a key disease
affecting grapes and other high-value fruit and vegetable crops.  It is
approved for sale in a number of key countries whilst Eden and its partners
pursue regulatory clearance in new territories thereby growing Eden's
addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's Sustaine®( )encapsulation technology is used to harness the biocidal
efficacy of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to enhance their
performance and ease-of-use. Sustaine microcapsules are naturally-derived,
plastic-free, biodegradable micro-spheres derived from yeast. It is one of the
only viable, proven and immediately registerable solutions to the
microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/)  .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUPGPAPUPGPUG